| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $3.5M | — | +9.3% |
| SG&A Expense | $1.4M | — | +30.8% |
| Operating Income | -$5.0M | — | -14.7% |
| Net Income | -$4.9M | — | -14.8% |
| EPS (Basic) | -$7.30 | — | -362.0% |
| EPS (Diluted) | -$7.30 | — | -362.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $3.0M | -59.0% | -77.4% |
| Current Assets | $4.1M | -49.7% | -70.3% |
| Total Assets | $4.7M | -46.0% | -66.2% |
| Current Liabilities | $4.6M | +11.7% | +64.9% |
| Total Liabilities | $4.6M | +11.7% | +64.9% |
| Stockholders' Equity | $71K |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$4.6M | — | -43.4% |
| Capital Expenditures | $6K | — | — |
| Investing Cash Flow | -$6K | — | — |
| Financing Cash Flow | $405K | — | -95.9% |
| Free Cash Flow | -$4.7M | — | -43.6% |
| -99.4% |